Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)

Labcorp Holdings raised guidance, triggering a sharp stock price rally. I view LH as a compelling long-term growth story, but current valuation is stretched. The price-earnings ratio approaching 20 exceeds my preferred range for LH's fundamentals.

Seeking Alpha • 12 hours ago

Labcorp Targets Margin Growth, Absorbs Policy Headwinds

Labcorp Holdings (NYSE:LH) stock is trading at a 52-week high after the company reported upbeat third-quarter earnings and raised its fiscal outlook.

Benzinga • Oct 28, 2026

Labcorp Q3 Earnings Call Highlights

Labcorp NYSE: LH reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of its full-year revenue and earnings outlook.

MarketBeat • Oct 28, 2026

Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript

Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 28, 2026

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

Results from operations for third quarter 2026 versus third quarter 2025: Revenue: $3.81 billion vs. $3.56 billion, up 6.9% Diluted EPS: $3.22 vs.

PRNewsWire • Oct 28, 2026

Labcorp Holdings (LH) Q3 Earnings and Revenues Surpass Estimates

Labcorp Holdings (LH) came out with quarterly earnings of $4.78 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings of $4.18 per share a year ago.

Zacks Investment Research • Oct 28, 2026

Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Oct 28, 2026

LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Up

Labcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.

Zacks Investment Research • Oct 28, 2026

Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests

WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.

Zacks Investment Research • Oct 27, 2026

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C.

PRNewsWire • Oct 23, 2026